Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II single-arm study of vorolanib in inoperable progressive or symptomatic desmoid tumors
ChiCTR2500101139Phase 2Recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- Apr 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of vorolanib in aggressive fibromatosis (AF), sponsored by West China Hospital of Sichuan University. Primary endpoint: Progression-free survival rate at 24 weeks. Started Apr 2025; status: recruiting.
02
Drugs
vorolanib
03
Conditions
aggressive fibromatosis (AF)
Beyond the preview
Go deeper on ChiCTR2500101139.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500101139.